Company intelligence / Profile preview

Bionoxx

Seongnam-Si, Gyeonggi-do, South Koreabionoxx.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Bionoxx has developed a novel immunomodulatory platform, BNX‑IFS, focused on neutrophil-directed T cell modulation. Its lead program, mOTS‑412 (an oncolytic virus), is entering first-in-human trials for patients with immune checkpoint inhibitor-resistant solid tumors. Preclinical data show enhanced cancer-specific cytotoxic T cell immunity and synergy with ICIs in resistant models.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Oncolytic virusCell therapyCAR-T cell therapy
Industry: Biotech

Drug pipeline

4 assets

OTS-412

3 more assets in the full pipeline.

Request access →

Partnerships

Currently seeking partners/collaborators for discovery/development of cancer and immune-mediated disease therapies; no major partnerships publicly disclosed yet.

Beyond the preview

Go deeper on Bionoxx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bionoxx.

Explore the full profile